Choosing Between
a Raise and
a Sale

I have had two founders in the same month show me P&Ls close enough to be the same business. One of them should have raised. The other should have sold. Nothing in the numbers decided that, and in my experience the numbers rarely do.

Both sides of the table have taught me the same lesson here. At WIN Brands Group we co-founded a DTC acquirer and ran buy-side diligence over and over. I sourced and closed a category-defining DTC acquisition for a consumer-goods company in the S&P 500, a several-hundred-million transaction at a double-digit EBITDA multiple, and we lifted profitability 18 percent within months of close. I advised a beauty brand through a nine-figure sale, and I founded and sold getuptime.co to Tiny. The founders who came out of those processes happiest were not the ones who got the highest number. They were the ones who had already answered a question that has nothing to do with valuation.

This sits next to the 12-month sell-side playbook, which assumes you have decided to sell, and next to the fundraising narrative piece, which assumes you have decided to raise. This one is about the fork itself.

The same numbers
point both ways.

Investors and acquirers underwrite the same inputs. EBITDA and the quality of it, cohort behavior, channel concentration, founder dependency, gross margin durability. Nobody is looking at a secret extra metric. What differs is the direction they look. Those are the same inputs the exit-readiness scorecard grades, which is why the score is worth having whichever door you end up walking through.

A sale is priced off what the last twelve months were, plus what the buyer believes they can do with it. A raise is priced off what the next three years could be, if you are right. Which means a brand with a strong trailing year and a thin forward story sells better than it raises, and a brand with a modest trailing year and a genuine forward story raises better than it sells. Same company, two different readings, and the reading you get is mostly determined by which room you walked into.

So the decision variable is not valuation. It is time and control. How many more years do you want to run this business, and who are you willing to answer to while you do. Everything else is downstream of that.

The thing that gets missed: a raise feels like the reversible option and it is not. A priced round sets a floor you now have to clear, adds a preference stack that sits ahead of you in any future outcome, and adds a clock, because a fund has a life and needs a return inside it. You have not delayed the exit decision. You have sold a piece of it to people who will have opinions about the timing.

What the money
actually buys.

In a consumer brand there are a small number of honest uses for a round. Inventory ahead of demand you can already prove, a channel expansion where you know the payback period, and a team you cannot fund out of cash flow. Everything else is usually a story about buying growth you have not earned, and the paid channels will take the money and hand back a worse blended CAC.

Understand the market you are raising into. Reported figures put DTC venture investment down roughly 97 percent from the 2021 peak to the 2023 trough, the steepest correction the category has had. The median consumer seed round fell below $1M in the first quarter of 2025, and the gap from seed to Series A stretched toward three years, close to double what it was in 2022. What replaced the old pattern in 2026 is a split market: large funds writing large checks at the top, and a near decade-low drought at seed.

Our own 2026 consumer funding tracker shows the shape of what is actually getting funded. Across the rounds logged through late July, most sit in the $3M to $20M band at seed and Series A, food and beverage leads by a wide margin with wellness second, and the checks are underwriting proven demand rather than a blitzscale plan. The scaled exceptions are real but they are exceptions.

For a $20M brand, that adds up to something specific. The round available to you is probably smaller and more expensive than the one in your model, and the diligence will look uncomfortably like a buyer's. It is also worth asking whether you need equity at all. If the constraint is inventory or customer acquisition, non-dilutive financing solves a narrower problem without selling a permanent piece of the company.

The failure mode to take seriously: raising at a number your trailing performance never grows into. The next event is a down round or a sale below the last round, and at that point the preference stack decides what the founder receives, which is often much less than the headline suggests. I have watched capable operators at $20M to $40M get hurt badly here, and in every case the round felt like a win the week it closed.

What a sale
actually costs.

Founders negotiate the headline and then discover the walk-down. Enterprise value is where the conversation starts, and what lands in your account is several steps below it.

Earnouts deserve their own paragraph because they have quietly become normal. SRS Acquiom put them at roughly 22 percent of deals in 2024, and most now measure revenue rather than EBITDA. Read what that means for your life: you keep operating toward a target, inside somebody else's approval process, for the period that determines whether you see the back half of your number. The multiple you negotiated matters less than whether that target is achievable under their budget.

Then there is the time cost. That Bayes Business School study puts average due diligence at 203 days, and advisory tallies of failed deals suggest roughly a third of signed LOIs never reach close, with buyer diligence findings and quality-of-earnings discrepancies leading the causes. The deals that do close are the more instructive number. Terms move between signing and closing far more often than they hold, so the price on the LOI is a starting position, not an outcome. What you expect at the beginning is rarely what you sign at the end. A process that dies in month five costs you a year of attention and sometimes your senior team, because people find out. The red flags piece is the buy-side version of why those deals die.

The part nobody writes down: most founders I know who sold and stayed through an earnout describe the second year as the hardest of their career. They kept the responsibility and lost the authority. Some would do it again. Very few enjoyed it.

For what the market is actually paying, the 2026 multiples read has the bands, and the realistic exit math on a $325M outcome shows the walk-down with real numbers attached. Our exits tracker logged 159 consumer acquisitions and control deals in the first seven months of 2026, with disclosed strategic EBITDA multiples clustering in the low to mid teens. None of this is legal, tax, or investment advice, and the tax treatment alone deserves an hour with someone licensed to give it.

Four questions that
actually decide it.

How many more years do you want to run this. Under three years points toward a sale, because a round you take now commits you to a five to seven year outcome whether you want it or not. Over seven years points toward a raise or toward neither, since you have time for the compounding to do the work. The dishonest answers here are the ones founders give in front of their boards.

What is the binding constraint, and does money fix it. Capital fixes inventory timing, a proven channel you cannot fund, and a hiring gap. It does not fix a demand problem or a margin problem. Pour money into either of those and you reach the same wall faster with more owners watching. If you are unsure which constraint you are actually against, the growth scorecard names the binding one in about 90 seconds.

Who else has a claim on the answer. Existing preferred holders with a liquidation preference, a co-founder on a different timeline, a spouse who has carried the household risk for six years. Get those positions on the table before you talk to a banker, because discovering a misalignment in week eight of a process is how deals die badly, slowly, and in front of your team.

What does the next twelve months look like if you change nothing structural. If trailing performance improves materially on its own, both options get better and waiting is the highest-return move available. If it flattens or declines, waiting is expensive and the window narrows. This is the question that most often produces a third answer.

The year where the
answer is neither.

At $20M to $40M with single-digit EBITDA, the right answer is often to do neither this year. A brand sitting at the 7 to 8 percent EBITDA line is at the threshold buyers underwrite, and each point of margin above it moves both the number and the basis the number is applied to. Twelve months of unglamorous margin work will frequently move the outcome more than either process would have.

My cleanest evidence for this is uncomfortable. On the S&P 500 acquisition I mentioned, profitability rose 18 percent within months of close. Almost none of that came from capital or from anything only a large acquirer could do. It came from work the seller could have done themselves and captured in their own price. They handed that value to the buyer because they went to market before doing it.

A margin year has a specific shape. Get to the profit line buyers actually underwrite. Break the founder dependency so the business is legible without you, which is the single biggest driver of how much of your price arrives as cash rather than earnout. Fix any channel, customer, or supplier concentration above 25 to 30 percent, since that is where the discount gets applied. And keep the data room current, so an unsolicited inbound finds you ready instead of scrambling.

I want to be honest about when this is wrong. If your category is consolidating and the acquirers are actively buying, a window can close while you are optimizing, and the way consumer brands die is rarely a sudden event. If you are personally finished, sell into a decent market rather than commit to a great year you do not have the energy to run. A tired founder running a margin program produces neither the margin nor the year.

Running both
at once.

Dual-tracking a raise and a sale is a real strategy and bankers like it, because two live options improve the terms on both. It works when your trailing performance is strong enough that either audience would want you on its own merits.

The cost is operational. You double the diligence load on a finance team that is probably one or two people, and the two audiences want the story pointed in opposite directions, forward for investors and backward for acquirers. A sloppy dual track ends with both sides sensing they are the fallback, and acquirers who learn you are also raising will sometimes just wait for the round to fail.

One prerequisite makes it survivable: a single maintained room with a forward layer and a legal layer, ready before either conversation starts. Without that, dual-tracking is just two half-processes competing for the same overworked controller. The 2026 exit lessons are mostly lessons about preparation.

Before either process, I ask founders one question that has nothing to do with money. Describe what you want to be doing 24 months from now, on a Tuesday morning, in specific terms. Most people answer immediately and clearly. Then they notice that the answer contradicts the option they were about to pick, and that is the most useful thing that happens in the conversation.